Bloomberg Law
Health Law & Business
LinkedIn

AbbVie Says FDA Approves Qulipta for Treatment of Migraine

Sept. 28, 2021, 10:45 PM UTC
Hari Govind
Hari Govind
Bloomberg News

AbbVie said the FDA approved Qulipta for the preventive treatment of episodic migraine in adults.

  • Qulipta is the first and only oral calcitonin gene-related peptide CGRP receptor antagonist gepant specifically developed for the preventive treatment of migraine

To view the source of this information, click here

To contact the reporter on this story:
Hari Govind in San Francisco at hgovind@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2021 Bloomberg L.P. All rights reserved. Used with permission.

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.